abs401.txt	until	recently		palliative	options	for	the	treatment	of	platinum-refractoryrecurrent	or	metastatic	head	and	neck	squamous	cell	carcinoma	(r/m	hnscc)	havebeen	cytotoxic	chemotherapy	egfr	inhibitors	these	agents	offer	limitedefficacy	with	substantial	toxicity	development	novel	immune	checkpointinhibitors	has	challenged	standard	pembrolizumab	is	a	potent	andhighly	selective	humanized	monoclonal	antibody	that	blocks	interactionbetween	pd-1	an	checkpoint	receptor	its	ligands	pd-l1	-2	inaugust	2016	us	fda	approved	use	in	r/m	hnscc	followingdisease	progression	on	after	platinum-containing	this	reviewhighlights	pharmacology	therapeutic	efficacy	tolerability	data	relevantto	readers	will	gaingreater	insight	into	tumor	microenvironment	available	biomarkers	andlearn	about	important	clinical	considerations	associated	ofpembrolizumab	similar
